Observational Study
Copyright ©The Author(s) 2016.
World J Cardiol. Feb 26, 2016; 8(2): 231-239
Published online Feb 26, 2016. doi: 10.4330/wjc.v8.i2.231
Table 1 Clinical, biochemical and vascular markers of the study population
VariablesValues (n = 70)
Clinical
Age (yr)60.2 ± 9.8
Gender (males), n (%)59 (84.3)
Hypertension, n (%)38 (54.2)
DM, n (%)23 (32.8)
Dyslipidemia, n (%)57 (81.4)
Smoking, n (%)43 (61.5)
FH of CAD, n (%)25 (35.7)
SBP (mmHg)128 ± 18
DBP (mmHg)77 ± 10
Medications
ASA n (%)70 (100)
Nitrates n (%)38 (54.3)
ACEIs/ARBS n (%)59 (84.2)
CCBs n (%)12 (17.1)
Statins n (%)65 (92.8)
β-blockers n (%)60 (85.5)
Biochemical
Chol (mg/dL)198.8 ± 40.8
TG (mg/dL)148.2 ± 79.9
HDL (mg/dL)40.9 ± 11.4
LDL (mg/dL)134.5 ± 35.9
Glu (mg/dL)106.5 ± 32.5
CRP (mg/L)2.44 ± 1.66
Lp-PLA2 (ng/mL)231.9 ± 90.9
Vascular markers
CFR2.65 ± 0.94
RHI-PAT1.37 ± 0.43
PWVc (m/s)10.32 ± 2.39
AIx (%)35.8 ± 15.4
SAI (%)50.6 ± 8.7
DAI (%)49.4 ± 8.7
DRA45.4 ± 12.6
RT (ms)115.1 ± 22.5
SBPc (mm Hg)133.2 ± 19.6
DBPc (mmHg)83.3 ± 12.4
FH: Family history; CAD: Coronary artery disease; DM: Diabetes mellitus; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; ASA: Acetylsalycilic acid; ACEIs: Angiotensin converting enzyme inhibitors; ARBs: Angiotensin receptors blockers; CCBs: Calcium channel blockers; Chol: Total cholesterol; TG: Triglycerides; LDL: Low density; HDL: High density lipoprotein; FPG: Fasting plasma glucose; CRP: C-reactive protein; Lp-PLA2: Lipoprotein-phospholipase A2 patients with multivessel coronary artery disease before revascularisation; CFR: Coronary flow reserve; PWVc: Pulse wave velocity as measured with complior apparatus; AIx: Augmentation index; SAI: Systolic area index; DAI: Diastolic area index; DRA: Diastolic reflection area; RT: Return time; SBPc: Central systolic blood pressure.
Table 2 Clinical and biochemical parameters of the study population divided by the median value of coronary flow reserve
CFR < 2.5(n = 34)CFR≥2.5(n = 36)P
Clinical
Age (yr)62.1 ± 9.258.4 ± 10.50.265
Males, n (%)29 (85.2)30 (83.3)0.869
Hypertension, n (%)20 (58.8)18 (50)0.368
Diabetes, n (%)13 (38.2)10 (27.7)0.631
Dyslipidemia, n (%)28 (82.3)29 (80.5)0.307
Smoking, n (%)23 (67.6)20 (55.5)0.449
FH of CAD14 (41.1)11 (30.5)0.334
SBP (mmHg)130.9 ± 20.3120.4 ± 14.80.011
DBP (mmHg)77.4 ± 10.474.8 ± 8.80.058
Medications
ASA, n (%)33 (97)34 (94.4)0.942
Nitrates, n (%)23 (67.6)27 (75)0.131
ACEIs/ARBS, n (%)33 (97)34 (94.4)0.956
CCBs, n (%)5 (14.7)7 (19.4)0.597
Statins, n (%)32 (94.1)33 (91.6)0.547
β-blockers, n (%)29 (85.2)31 (86.1)0.765
Biochemical
Chol (mg/dL)206.7 ± 44.1190.6 ± 38.90.078
TG (mg/dL)147.0 ± 57.1143.9 ± 69.70.824
HDL (mg/dL)39.6 ± 8.640.9 ± 12.80.567
LDL (mg/dL)141.6 ± 37.8126.6 ± 32.90.055
Glu (mg/dL)100.9 ± 2 2.7112.4 ± 39.90.126
CRP (mg/L)2.5 ± 1.82.4 ± 1.50.279
Lp-PLA2 (ng/mL)268.1 ± 91.9199.5 ± 78.40.002
Vascular markers
RHI-PAT1.26 ± 0.281.50 ± 0.460.012
PWVc (m/s)11.6 ± 2.310.2 ± 1.40.019
AIx (%)38.2 ± 14.829.4 ± 15.10.011
SAI (%)55.7 ± 7.946.1 ± 6.70.008
DAI (%)44.3 ± 7.953.9 ± 6.70.008
DRA42.2 ± 9.651.6 ± 11.40.012
RT (ms)106.1 ± 20.8123.0 ± 22.10.015
SBPc (mm Hg)139.1 ± 17.8125.2 ± 19.10.026
DBPc (mmHg)84.7 ± 12.180.0 ± 11.00.118
FH: Family history; CAD: Coronary artery disease; DM: Diabetes mellitus; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; ASA: Acetylsalycilic acid; ACEIs: Angiotensin converting enzyme inhibitors; ARBs: Angiotensin receptors blockers; CCBs: Calcium channel blockers; Chol: Total cholesterol; TG: Triglycerides; LDL: Low density; HDL: High density lipoprotein; FPG: Fasting plasma glucose; CRP: C-reactive protein; Lp-PLA2: Lipoprotein-phospholipase A2 patients with multivessel coronary artery disease before revascularisation; CFR: Coronary flow reserve; PWVc: Pulse wave velocity as measured with complior apparatus; AIx: Augmentation index; SAI: Systolic area index; DAI: Diastolic area index; DRA: Diastolic reflection area; RT: Return time; SBPc: Central systolic blood pressure; DBPc: Central diastolic blood pressure.